Daniel Joseph McCarthy - 26 Aug 2026 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Reporting relationship: PRESIDENT
Issuer ticker: EVH
Reported as of: 26 Aug 2026
Net transaction value: -$329,460
SEC form: 4
Accepted by SEC: 28 Aug 2026, 16:17:06 UTC
Prior SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Weinberg, Attorney-in-fact

Key filing fact

Daniel Joseph McCarthy filed Form 4 for Evolent Health, Inc. (EVH) on 28 Aug 2026.

Key facts

This page summarizes Daniel Joseph McCarthy's Form 4 filing for Evolent Health, Inc. (EVH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Aug 2026, 16:17.

Change

Previous filing in this sequence was filed on 06 Jul 2026.
Current net transaction value: -$329,460.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001946147 Primary reporting owner

McCarthy Daniel Joseph

Relationship: PRESIDENT
Address: C/O EVOLENT HEALTH, INC., 1812 N. MOORE ST., STE. 1705, ARLINGTON
Signature: /s/ Jonathan Weinberg, Attorney-in-fact
Signature date: 28 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVH transaction

Class A Common Stock

Sale

Transaction value: $329,460
Shares: -65,892
Change %: -9.1%
Price: $5.00
Shares after: 655,133
Date: 26 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026.

Footnote F2

Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.